These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 34142298

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Increased frequency of hospital admissions with active systemic lupus erythematosus disease activity defined by two different disease activity indices: A cohort study.
    Wang CL, Koo M, Hsu CW, Lu MC.
    Lupus; 2023 Jun; 32(7):864-872. PubMed ID: 37165549
    [Abstract] [Full Text] [Related]

  • 25. Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE.
    Cody EM, Wilson BE, Ogbu EA, Huggins JL, Chen C, Qiu T, Ting TV, Flores F, Huang B, Brunner HI.
    Lupus Sci Med; 2023 May; 10(1):. PubMed ID: 37253553
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study.
    Saraiva L, Cunha RN, Jesus D, Gatto M, Zen M, Iaccarino L, da Silva JAP, Doria A, Inês LS.
    Rheumatology (Oxford); 2024 Apr 02; 63(4):1123-1129. PubMed ID: 37458482
    [Abstract] [Full Text] [Related]

  • 28. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study.
    Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y, Li ZG, Luo SF, Sockalingam S, Lau CS, Mok MY, Lateef A, Franklyn K, Morton S, Navarra ST, Zamora L, Wu YJ, Hamijoyo L, Chan M, O'Neill S, Goldblatt F, Nikpour M, Morand EF, Asia-Pacific Lupus Collaboration.
    Arthritis Res Ther; 2017 Mar 20; 19(1):62. PubMed ID: 28320433
    [Abstract] [Full Text] [Related]

  • 29. 'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.
    Kandane-Rathnayake R, Louthrenoo W, Hoi A, Luo SF, Wu YJ, Chen YH, Cho J, Lateef A, Hamijoyo L, Navarra SV, Zamora L, Sockalingam S, An Y, Li Z, Katsumata Y, Harigai M, Hao Y, Zhang Z, Kikuchi J, Takeuchi T, Basnayake BMDB, Chan M, Ng KPL, Tugnet N, Kumar S, Oon S, Goldblatt F, O'Neill S, Gibson KA, Ohkubo N, Tanaka Y, Bae SC, Lau CS, Nikpour M, Golder V, Morand EF, Asia-Pacific Lupus Collaboration.
    Arthritis Res Ther; 2022 Mar 14; 24(1):70. PubMed ID: 35287720
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.
    Morand EF, Isenberg DA, Wallace DJ, Kao AH, Vazquez-Mateo C, Chang P, Pudota K, Aranow C, Merrill JT.
    Rheumatology (Oxford); 2020 Oct 01; 59(10):2930-2938. PubMed ID: 32107560
    [Abstract] [Full Text] [Related]

  • 32. How can we define low disease activity in systemic lupus erythematosus?
    Tselios K, Gladman DD, Urowitz MB.
    Semin Arthritis Rheum; 2019 Jun 01; 48(6):1035-1040. PubMed ID: 30415943
    [Abstract] [Full Text] [Related]

  • 33. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.
    Touma Z, Gladman DD, Ibañez D, Taghavi-Zadeh S, Urowitz MB.
    J Rheumatol; 2011 Nov 01; 38(11):2395-9. PubMed ID: 21885488
    [Abstract] [Full Text] [Related]

  • 34. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus.
    Uribe AG, Vilá LM, McGwin G, Sanchez ML, Reveille JD, Alarcón GS.
    J Rheumatol; 2004 Oct 01; 31(10):1934-40. PubMed ID: 15468356
    [Abstract] [Full Text] [Related]

  • 35. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
    Floris A, Piga M, Perra D, Chessa E, Congia M, Mathieu A, Cauli A.
    Arthritis Care Res (Hoboken); 2020 Dec 01; 72(12):1794-1799. PubMed ID: 31600023
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study.
    Golder V, Kandane-Rathnayake R, Huq M, Louthrenoo W, Luo SF, Wu YJ, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, Goldblatt F, Lau CS, Li ZG, Hoi A, Nikpour M, Morand EF, Asia Pacific Lupus Collaboration.
    Lancet Rheumatol; 2019 Oct 01; 1(2):e103-e110. PubMed ID: 38229337
    [Abstract] [Full Text] [Related]

  • 37. The correlation between pregnancy, disease activity and adverse pregnancy outcomes in patients with systemic lupus erythematosus.
    Çetin Ç, Saraç-Sivrikoz T, Ateş-Tıkız M, Zaralı S, Ersoy A, Yalçınkaya Y, Gül A, İnanç M, Has R, Kalelioğlu İ, Artım Esen B.
    Lupus; 2023 Nov 01; 32(13):1509-1517. PubMed ID: 37855206
    [Abstract] [Full Text] [Related]

  • 38. Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up.
    Parodis I, Stephens T, Dominicus A, Eek D, Sjöwall C.
    Rheumatology (Oxford); 2024 Feb 24. PubMed ID: 38402496
    [Abstract] [Full Text] [Related]

  • 39. LLDAS is an attainable treat-to-target goal in childhood-onset SLE.
    Wahadat MJ, van den Berg L, Timmermans D, van Rijswijk K, van Dijk-Hummelman A, Bakx S, Verkaaik M, Versnel MA, Kamphuis S.
    Lupus Sci Med; 2021 Dec 24; 8(1):. PubMed ID: 34969874
    [Abstract] [Full Text] [Related]

  • 40. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients.
    Yee CS, Farewell VT, Isenberg DA, Griffiths B, Teh LS, Bruce IN, Ahmad Y, Rahman A, Prabu A, Akil M, McHugh N, Edwards C, D'Cruz D, Khamashta MA, Gordon C.
    Rheumatology (Oxford); 2011 May 24; 50(5):982-8. PubMed ID: 21245073
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.